about
Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3Vitamin D and VDR in cancer cachexia and muscle regeneration.Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition.Caspase 2 activation and ER stress drive rapid Jurkat cell apoptosis by clofibrateβ-hydroxy-β-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia.Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exerciseA Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan.Ca(2+)-dependent proteolysis in muscle wasting.Molecular and cellular mechanisms of skeletal muscle atrophy: an update.Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.Autophagy is induced in the skeletal muscle of cachectic cancer patients.Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma.Cytotoxic properties of clofibrate and other peroxisome proliferators: relevance to cancer progression.Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia.Coming back: autophagy in cachexia.Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy.Experimental cancer cachexia: Evolving strategies for getting closer to the human scenario.Autophagic degradation contributes to muscle wasting in cancer cachexia.A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy.Glutamine prevents myostatin hyperexpression and protein hypercatabolism induced in C2C12 myotubes by tumor necrosis factor-α.Mechanisms of clofibrate-induced apoptosis in Yoshida AH-130 hepatoma cells.Differences in food intake of tumour-bearing cachectic mice are associated with hypothalamic serotonin signalling.Interference with Ca2+-Dependent Proteolysis Does Not Alter the Course of Muscle Wasting in Experimental Cancer Cachexia.Are there any benefits of exercise training in cancer cachexia?Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients.Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency?Muscle myostatin signalling is enhanced in experimental cancer cachexia.Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing mice.The role of vitamin D in cancer cachexia.Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?Modulating Metabolism to Improve Cancer-Induced Muscle Wasting.Involvement of released sphingosine 1-phosphate/sphingosine 1-phosphate receptor axis in skeletal muscle atrophyIGF-1 is downregulated in experimental cancer cachexiaModerate Exercise Improves Experimental Cancer Cachexia by Modulating the Redox HomeostasisInterleukin-4 administration improves muscle function, adult myogenesis, and lifespan of colon carcinoma-bearing miceNew developments in investigational HDAC inhibitors for the potential multimodal treatment of cachexiaModerate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations
P50
Q28542391-B79D6F9B-70FC-40AD-A7E8-6C7B3A80B64CQ33591678-783D24C7-B5E4-488C-AA0E-2C079CB67107Q33737527-E51CF2A7-773A-44A6-BA13-F055BCB12815Q34428761-5DA22D5D-8CA6-4D8D-B75D-E04B96EE86F1Q34626024-BB08028D-0886-47D1-B834-F1093A5D3BF1Q35053606-65074A48-4F81-456B-BECD-A531DB4A62F5Q35875208-40FC99B8-13D4-4941-9914-1B0219DDE93EQ36127683-1FC0CD7F-B0AD-4AFD-87DA-4EDA04EED8C9Q36179105-71A5257B-0CB9-4640-927C-2DA97621ED94Q36893329-EE32AF9A-F461-4E43-830D-26C140B788C6Q37128604-61D9A66B-4274-4AF3-A761-14B4E0603C9FQ37464647-BDF64B66-1938-4310-BA5D-3416F21BA1C0Q37656449-27D22BAE-E47D-4439-8D96-1EEA3136BBF6Q37769250-D748F15F-E288-486D-8D7E-667A643876ADQ38188822-D7FA58A9-7FE1-488A-8190-470E1CC74A32Q38302624-4C414B6C-CAC5-44DB-BD98-5BB52A2EA3A4Q38581853-AAD6D85B-440C-4E18-8E31-74A20FD7D725Q39197324-970CA2AB-B158-4122-958F-46CD60DC61EFQ39218137-50D9F12F-17CD-4F7A-A86C-3BF7F697ABFEQ39681574-4201FCBB-8B3D-46D8-8904-ACE30A4B2D2AQ39921446-12CD8666-5E6A-4126-AA61-753A92B8D6D8Q40771496-1AA0D6F7-25FC-4CE8-AB65-147978BC2061Q42155053-FA7059CC-6F43-4F39-BBA1-C92350EBA625Q42199742-87AA08E4-A7D8-455B-B956-7E0D940A4000Q43820079-F916D25B-23DA-43D5-A8D0-F329B9EF8512Q44996842-D3D87131-87AC-49D7-9311-5E92280A93AAQ46519828-94A12D48-BC33-4765-8A2A-C420490809FCQ46635433-CF2C0C22-5D49-4A72-BF3F-DE62D06F9E76Q47117911-43708A2A-18E7-4751-9104-8F2BF277A836Q47967776-8548F7CF-9F0C-4BB4-9257-DAA42A0F9E4BQ54448314-423027AE-551A-40D6-BA94-2B5E4D460AC7Q55301138-1358ED77-8D4B-4799-97FC-70C1BB33215EQ57120043-23038810-DC35-4794-8B09-BBEA922EA616Q60403681-464C33E3-B486-4FC3-93CB-B6808CB4FCBDQ64086636-EEDE1A58-9C6F-47E9-8FF6-3BBA77CED7B2Q89905217-E36D432F-2CE8-4DEA-A10C-372D5BEE3BE7Q90334400-850E274E-6B05-4307-A29B-7440B86FE8ADQ91088408-C1871B34-A20F-4AA2-9DE2-FFA065EFCB33
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fabio Penna
@ast
Fabio Penna
@en
Fabio Penna
@es
Fabio Penna
@nl
type
label
Fabio Penna
@ast
Fabio Penna
@en
Fabio Penna
@es
Fabio Penna
@nl
prefLabel
Fabio Penna
@ast
Fabio Penna
@en
Fabio Penna
@es
Fabio Penna
@nl
P106
P1153
8668157200
P21
P31
P496
0000-0002-2774-6027